One Off Flat-Rate Subscription to Life Science Reports & News Services

Dublin, Dec. 14, 2017 -- The "Flat-Rate Subscription to La Merie Publishing Reports & News Services" newsletter has been added to Research and Markets' offering.

Flat-Rate Subscription to La Merie Publishing Reports & News Services

A one-year subscription to this service provides access to:

• All existing La Merie Publishing reports on stock and listed online in the store;
• All new reports released by La Merie Publishing during the term of the subscription;
• 50 (weekly) issues of R&D Pipeline News

Among these reports are:

• Competitor Analysis reports in tabular presentation format;
• Brief Reports; and
• Full Reports.

Publishing activities include updates of existing reports as well as release of new reports.

Among La Merie Publishing News & Information Services are:

• R&D Pipeline News - Technology Edition;
• R&D Pipeline News - Therapeutic Area Edition.

After purchase of the Flat-Rate Subscription to La Merie Publishing Reports & News Services, credentials to access a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.

Coverage of reports:

La Merie Publishing has a special focus on biologics including, but not limited to:

• mRNA vaccines & therapeutics
• Oncolytic viruses
• Antibody-drug conjugates;
• Bispecific antibodies including T-cell or NK cell redirecting antibodies
• CAR & TCR engineered T-cells and NK cells;
• Immuno-oncology;
• Biosimilar antibodies and proteins
• Biosuperior antibodies;
• Therapeutic proteins;
• Therapeutic and prophylactic vaccines;
• Therapeutic peptides.

Reports of the Competitor Analysis Series deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases and technologies provided in a tabular format and fully referenced.

Full Reports and Brief Reports provide in-depth description and analysis of targets, pipelines, companies and technologies.

Examples of Full Reports as of October 2017 are:

• mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals
• The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities
• TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs
• T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Examples of Brief Reports as of October 2017 are:

• CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
• CD123: a paradigmatic target for immunotherapeutic treatment modalities
• B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Examples of Competitor Analysis Reports as of October 2017 are:

• Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017
• Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company
• Tumor Microenvironment Modulation via IDO, TGF-/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others
• Biosimilar and Biosuperior Therapeutic Antibodies
• PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016
• Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

Examples of Vaccine Reports

• Clostridium Difficile Vaccines and Therapeutics 2016
• Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Examples of Peptide Reports

• Cancer Peptides
• Cardiometabolic Peptides
• Anti-Infective Peptides
• Cardiovascular Peptides
• Anti-Inflammatory Peptides

For more information about this newsletter visit https://www.researchandmarkets.com/research/pszsff/one_off_flatrate?w=12

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmaceuticals